Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation

Cao,Guoying; Zhu,Yongjun; Xie,Xin; Chen,Yuancheng; Yu,Jicheng; Zhang,Jing; Chen,Zhiming; Pang,Liewen; Zhang,Yingyuan; Shi,Yaoguo

doi:10.3892/etm.2020.8715

Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation

Authors:
- Guoying Cao
- Yongjun Zhu
- Xin Xie
- Yuancheng Chen
- Jicheng Yu
- Jing Zhang
- Zhiming Chen
- Liewen Pang
- Yingyuan Zhang
- Yaoguo Shi
View Affiliations

Affiliations: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: May 5, 2020 https://doi.org/10.3892/etm.2020.8715
Pages: 607-616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Levofloxacin is a major antimicrobial agent that is used for the treatment of community‑acquired lower respiratory tract infections (LRTIs). The present study was designed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of levofloxacin in bronchial mucosa and lung tissue. A total of 32 patients undergoing pulmonary surgery were randomly assigned to one of four groups (8 subjects/group). All patients received a single dose of 500 mg levofloxacin orally prior to the operation. Blood, lung tissue and bronchial mucosa samples were collected prior to treatment and at 1.5, 4, 8, 12 and 24 h following treatment. The drug concentration was determined and PK and PD profiles were calculated using MATLAB software. The peak concentration of levofloxacin was 7.0±1.2 µg/g in lung tissues and 9.4±2.1 µg/g in bronchial mucosa. The corresponding area under the curve between 0 and 24 h (AUC0‑24) was 85.7±8.5 and 137.3±19.4 µg h/g. The mean permeability of levofloxacin (ratio of concentration in tissue to that in plasma) was 2.4 in lung tissue and 4.4 in the bronchial mucosa. The PK profiles of levofloxacin in the plasma, lung and bronchial mucosa were described using an integrated one‑compartment model. The probability of fAUC0‑24/minimal inhibitory concentration (MIC) target attainment of levofloxacin against Streptococcus pneumoniae in the lung and bronchial mucosa was maintained at 100% when MIC ≤1 mg/l, while the cumulative fraction of fAUC0‑24/MIC in the corresponding tissues was 94.4 and 98.1%, respectively. The present study demonstrated the high permeability of levofloxacin in the lung and bronchial mucosa of patients undergoing pulmonary surgery. In conclusion, treatment using 500 mg levofloxacin exhibits good clinical and microbiological efficacy for use in LRTIs that are caused by S. pneumoniae. This trial was registered retrospectively in the Chinese Clinical Trial Registry on January 13, 2020 (registration no. ChiCTR2000029096).

View Figures

View References

1	Torres A and Liapikou A: Levofloxacin for the treatment of respiratory tract infections. Expert Opin Pharmacother. 13:1203–1212. 2012.PubMed/NCBI View Article : Google Scholar
2	Zhang J, Xie X, Zhou X, Chen YQ, Yu JC, Cao GY, Wu XJ, Shi YG and Zhang YY: Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. J Clin Pharmacol. 50:922–928. 2010.PubMed/NCBI View Article : Google Scholar
3	Nakajima T, Kaji Y and Miyawaki M: Penetration of single-dose levofloxacin into intestinal tissue. J Gastroen Hepatol Res. 2:399–402. 2013.
4	Hutschala D, Skhirtladze K, Zuckermann A, Wisser W, Jaksch P, Mayer-Helm BX, Burgmann H, Wolner E, Müller M and Tschernko EM: In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother. 49:5107–5111. 2005.PubMed/NCBI View Article : Google Scholar
5	Grossman RF, Rotschafer JC and Tan JS: Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med. 118 (Suppl)(29S-38S)2005.PubMed/NCBI View Article : Google Scholar
6	Andes D and Craig WA: Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents. 19:261–268. 2002.PubMed/NCBI View Article : Google Scholar
7	Friedman H, Song X, Crespi S and Navaratnam P: Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health. 12:1135–1143. 2009.PubMed/NCBI View Article : Google Scholar
8	Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, et al: Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study. Curr Med Res Opin. 25:859–868. 2009.PubMed/NCBI View Article : Google Scholar
9	Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D and Olson W: A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: Focus on length of stay. Curr Med Res Opin. 24:895–906. 2008.PubMed/NCBI View Article : Google Scholar
10	Lynch-JP III, File-TM Jr and Zhanel GG: Levofloxacin for the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 4:725–742. 2006.PubMed/NCBI View Article : Google Scholar
11	DiPiro JT: Short-term prophylaxis in clean-contaminated surgery. J Chemother. 11:551–555. 1999.PubMed/NCBI View Article : Google Scholar
12	Radu DM, Jauréguy F, Seguin A, Foulon C, Destable MD, Azorin J and Martinod E: Postoperative pneumonia after major pulmonary resections: An unsolved problem in thoracic surgery. Ann Thorac Surg. 84:1669–1673. 2007.PubMed/NCBI View Article : Google Scholar
13	Schussler O, Alifano M, Dermine H, Strano S, Casetta A, Sepulveda S, Chafik A, Coignard S, Rabbat A and Regnard JF: Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med. 173:1161–1169. 2006.PubMed/NCBI View Article : Google Scholar
14	Belda J, Cavalcanti M, Ferrer M, Serra M, Puig de la Bellacasa J, Canalis E and Torres A: Bronchial colonization and postoperative respiratory infections in patients undergoing lung cancer surgery. Chest. 128:1571–1579. 2005.PubMed/NCBI View Article : Google Scholar
15	Bratzler DW and Houck PM: Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical infection prevention project. Am J Surg. 189:395–404. 2005.PubMed/NCBI View Article : Google Scholar
16	Gupta R, Sinnett D, Carpenter R, Preece PE and Royle GT: Antibiotic prophylaxis for post-operative wound infection in clean elective breast surgery. Eur J Surg Oncol. 26:363–366. 2000.PubMed/NCBI View Article : Google Scholar
17	Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE, Wright C, Ma A, Carr K and Red L: Use of antimicrobial prophylaxis for major surgery: Baseline results from the National Surgical Infection Prevention Project. Arch Surg. 140:174–182. 2005.PubMed/NCBI View Article : Google Scholar
18	Malone DL, Genuit T, Tracy JK, Gannon C and Napolitano LM: Surgical site infections: Reanalysis of risk factors. J Surg Res. 103:89–95. 2002.PubMed/NCBI View Article : Google Scholar
19	Von Baum H, Böttcher S, Hoffmann H and Sonntag HG: Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. J Antimicrob Chemother. 47:729–730. 2001.PubMed/NCBI View Article : Google Scholar
20	Swoboda S, Oberdorfer K, Klee F, Hoppe-Tichy T, von Baum H and Geiss HK: Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. J Antimicrob Chemother. 51:459–462. 2003.PubMed/NCBI View Article : Google Scholar
21	Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41. 1976.PubMed/NCBI View Article : Google Scholar
22	Xie X, Zhang J, Yu JC, Shi YG and Zhang YY: HPLC assay of levofloxacin concentration in plasma, lung tissue, and body fluids. Chin J Clin Pharmacol Ther. 17:158–162. 2008.PubMed/NCBI View Article : Google Scholar
23	Chen Y, Cao Y, Zhou J and Liu X: Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats. Pharm Res. 26:1863–1673. 2009.PubMed/NCBI View Article : Google Scholar
24	Askenazi SS and Perlman M: Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis. Arch Dis Child. 54:614–618. 1979.PubMed/NCBI View Article : Google Scholar
25	Qi XL, Bo AH and Xia L: Determination of cerebral and lung weight of fetus. Chin J Birth Health Heredity. 65(65)1993.PubMed/NCBI View Article : Google Scholar
26	Jaruratanasirikul S, Jaspattananon A, Wongpoowarak W, Nawakitrangsan M, Thengyai S and Samaeng M: Population pharmacokinetics and pharmacodynamics modeling of oral levofloxacin. J Med Assoc Thai. 99:886–892. 2018.PubMed/NCBI
27	Cojutti PG, Ramos-Martin V, Schiavon I, Rossi P, Baraldo M, Hope W and Pea F: Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function. Antimicrob Agents Chemothe. 61(e02134-16)2017.PubMed/NCBI View Article : Google Scholar
28	Scaglione F, Mouton JW, Mattina R and Fraschini F: Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: Peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother. 47:2749–2755. 2003.PubMed/NCBI View Article : Google Scholar
29	Zhang YY, Huang HH and Ren ZY: Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: A prospective multicenter study in China. J Infect Chemother. 15:301–311. 2009.PubMed/NCBI View Article : Google Scholar
30	Cao G, Zhang J, Wu X, Yu J, Chen Y, Ye X, Zhu D, Zhang Y, Guo B and Shi Y: Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. J Clin Pharm Ther. 38:394–400. 2013.PubMed/NCBI View Article : Google Scholar
31	Rodvold KA, Danziger LH and Gotfried MH: Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and Azithromycin in healthy adults. Antimicrob Agents Chemother. 47:2450–2457. 2003.PubMed/NCBI View Article : Google Scholar
32	Conte JE Jr, Golden JA, McIver M, Little E and Zurlinden E: Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents. 30:422–427. 2007.PubMed/NCBI View Article : Google Scholar
33	Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J and Corrado M: Pharmacodynamics of levofloxac in: A new paradigm for early clinical trials. JAMA. 279:125–129. 1998.PubMed/NCBI View Article : Google Scholar
34	Zhang J, Yu JC, Shi YG, Zhou L, Ye XY, Zhu DM and Zhang YY: Study of pharmacokinetics/pharmacodynamics of levofloxacin. Zhonghua Yi Xue Za Zhi. 85:1926–1932. 2005.(In Chinese). PubMed/NCBI
35	Wu XJ, Zhang J, Guo BN, Zhang YY, Yu JC, Cao GY, Chen YC, Zhu DM, Ye XY, Wu JF, et al: Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers. Antimicrob Agents Chemother. 59:1446–1454. 2015.PubMed/NCBI View Article : Google Scholar
36	Lee LJ, Sha X, Gotfried MH, Howard JR, Dix RK and Fish DN: Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy. 18:35–41. 1998.PubMed/NCBI
37	Wang CQ, Wang W, Jin MH, Huang Q and Guan Q: Pulmonary resections in surgical treatment of lung tuberculosis. J Clin Pulmonary Med. 14:906–908. 2009.PubMed/NCBI View Article : Google Scholar
38	Li P, Mao YB and Liu CT: Risk factors for surgical site infections in patients undergoing pneumonectomy. Chin J Nosocomiol. 23(5198-5199-5202)2013.
39	Pea F: Intracellular pharmacokinetics of antibacterials and their clinical implications. Clin Pharmacokinet. 57:177–189. 2018.PubMed/NCBI View Article : Google Scholar
40	Moriarty TF, McElnay JC, Elborn JS and Tunney MM: Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol. 42:1008–1017. 2007.PubMed/NCBI View Article : Google Scholar
41	Kelly MM, Efthimiadis A and Hargreave FE: Induced sputum: Selection method. Methods Mol Med. 56:77–91. 2001.PubMed/NCBI View Article : Google Scholar
42	Cazzola M, Blasi F, Terzano C, Matera MG and Marsico SA: Delivering antibacterials to the lungs: Considerations for optimizing outcomes. Am J Respir Med. 1:261–272. 2002.PubMed/NCBI View Article : Google Scholar
43	Yu JC, Zhang J and Cao GY: Single-dose and multiple-dose pharmacokinetics of levofloxacin in Chinese healthy subjects. J Third Mil Med Univ. 35:2516–2520. 2013.
44	Simon N, Sampol E, Albanese J, Martin C, Arvis P, Urien S, Lacarelle B and Bruguerolle B: Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin Pharmacol Ther. 74:353–363. 2003.PubMed/NCBI View Article : Google Scholar
45	Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C and Nicolau DP: Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 125:965–973. 2004.PubMed/NCBI View Article : Google Scholar
46	Hutschala D, Kinstner C, Skhirtladze K, Mayer-Helm BX, Zeitlinger M, Wisser W, Müller M and Tschernko E: The impact of perioperative atelectasis on antibiotic penetration into lung tissue: An in vivo microdialysis study. Intensive Care Med. 34:1827–1834. 2008.PubMed/NCBI View Article : Google Scholar
47	Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A and Alffenaar JC: Pharmacokinetics of levofloxacin in multidrug- and extensively drug-resistant tuberculosis patients. Antimicrob Agents Chemother. 61(pii: e00343-17)2017.PubMed/NCBI View Article : Google Scholar
48	Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, et al: Fluoroquinolones in drug-resistant tuberculosis: Culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection. Antimicrob Agents Chemother. 63(pii: e00279-19)2019.PubMed/NCBI View Article : Google Scholar
49	U.S. Department of Health and Human Services. FDA guidance for industry: Population Pharmacokinetics, July 2019. https://www.fda.gov/media/128793/download. Accessed October 2019.